See the DrugPatentWatch profile for Exforge
What’s the key difference between Exforge and Azor?
Exforge is a brand for a combination of two blood-pressure medicines: amlodipine + valsartan. [1]
Azor is also a brand for a two-drug blood-pressure combination: amlodipine + olmesartan. [2]
So the main difference is the second drug:
- Exforge = valsartan (an ARB)
- Azor = olmesartan (an ARB)
Both contain amlodipine (a calcium-channel blocker) as the first component.
How do they compare as ARB combinations (valsartan vs olmesartan)?
Because both products pair the same calcium-channel blocker (amlodipine) with a different ARB, they are used for similar patient goals—improving blood pressure when one medicine alone is not enough. [1][2]
In practice, switching between the two products usually depends on which ARB a clinician prefers for a given patient, formulary coverage, tolerability, or prior response—rather than on a fundamentally different mechanism, since both ARBs act similarly by blocking the angiotensin receptor.
Are the dosing forms and “what you take per day” the same?
Both are fixed-dose combination tablets that combine amlodipine with an ARB, but the available strength combinations and titration options can differ by brand and generic/labeling. [1][2]
To compare exactly, you’d match the amlodipine strength and the ARB strength (valsartan in Exforge vs olmesartan in Azor) to your prescribed dose.
Which one might be easier to switch to if you’re already on an ARB?
If you’re already taking an ARB, the closest “functional match” is typically the combination that uses the same ARB class but swaps the specific ARB. Here, that means:
- someone on a valsartan-containing regimen may consider Exforge for continuity of the ARB, [1]
- someone on an olmesartan-containing regimen may consider Azor for continuity of the ARB. [2]
Your clinician still needs to account for dose equivalence and blood-pressure response.
What side effects are most relevant for both?
Because both products share amlodipine and an ARB, many side effects overlap (for example, effects related to calcium-channel blockers and ARBs). The most important safety issues with ARBs include monitoring for problems that can occur with kidney function changes or high potassium in susceptible patients, and standard ARB precautions apply.
If you tell me your current dose and which formulation you’re considering (and any kidney issues, high potassium, or prior intolerance), I can help you map the differences more precisely.
Sources
- DrugPatentWatch.com – Exforge (amlodipine/valsartan): https://www.drugpatentwatch.com/
- DrugPatentWatch.com – Azor (amlodipine/olmesartan): https://www.drugpatentwatch.com/